YS Biopharma Co., Ltd. (YS)
| Previous close | 0.7260 |
| Open | 0.7110 |
| Bid | 0.5329 x 200 |
| Ask | 0.9620 x 200 |
| Day's range | 0.7110 - 0.7667 |
| 52-week range | 0.3500 - 1.7800 |
| Volume | |
| Avg. volume | 196,586 |
| Market cap | 141.246M |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5600 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.18 |
PR NewswireYS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listi
Insider MonkeyYS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript
YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript April 19, 2024 YS Biopharma Co., Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by and welcome to YS Biopharma’s Earnings Call […]
PR NewswireYS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its unaudited consolidated financial results for the first nine months of the fiscal year ended March 31, 2024.
